Table 1 Participants’ characteristics

Age, years

52.7 ± 11.1

57.1 ± 10.9

57.3 ± 11.0

0.912

Male, n (%)

106 (89.8)

102 (91.1)

82 (85.4)

0.401

Hypertension, n (%)

42 (35.6)

54 (48.2)*

57 (59.4)*

0.002

Hyperlipidemia, n (%)

54 (45.8)

59 (56.2)

52 (54.2)

0.334

Diabetes mellitus, n (%)

17 (14.4)

18 (16.1)

23 (24.0)

0.175

Smoking, n (%)

85 (72.0)

80 (71.4)

62 (64.6)

0.052

BMI, kg/m²

25.9 ± 3.2

25.4 ± 2.9

26.3 ± 3.0

0.106

Anterior infarction, n (%)

67 (56.8)

53 (47.3)

39 (40.6)

0.059

Killip Class I on admission, n (%)

116 (98.3)

110 (98.2)

91 (94.8)

0.219

Maximum value of CK, IU/L

1421 ± 801

1370 ± 770

1460 ± 879

0.730

LVEDD, mm

49.6 ± 4.5

49.3 ± 6.8

50.3 ± 5.7

0.401

LVEF,%

57.1 ± 8.9

57.3 ± 10.1

55.9 ± 9.0

0.592

Gensini’s score

---

63.2 ± 37.0

65.2 ± 36.5

0.814

IRA

0.080

 LM, n (%)

0 (0)

0 (0)

0 (0)

 LAD, n (%)

70 (59.3)

57 (50.9)

38 (39.6)

 LCX, n (%)

16 (13.6)

18 (16.1)

18 (18.6)

 RCA, n (%)

32 (27.1)

37 (33.0)

40 (41.7)

Medication usage at the time of CPET, n (%)

 RAAS blockers

102 (86.4)

98 (87.5)

88 (91.7)

0.467

 ß-blockers

95 (80.5)

80 (71.4)

69 (71.9)

0.207

 Statins

101 (85.6)

95 (84.8)

80 (83.3)

0.900